| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Review |
Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, London W12 ONN, United Kingdom
1 Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
(Requests for offprints should be addressed to B Gellersen; Email: gellersen{at}endokrinologikum.com)
 |
Abstract |
|---|
 Top Abstract IntroductionDecidualisation of the...Transcription factors in...Progesterone - tipping the...PerspectiveReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionDecidualisation of the...Transcription factors in...Progesterone - tipping the...PerspectiveReferences |
|---|
The cyclical waves of proliferation, differentiation, shedding and regeneration of human endometrium, which occur on average 400 times during reproductive life, are unparalleled in any other tissue of the body. Within this cycle, decidualisation of the stromal compartment represents a tipping point after which the fate of the endometrium becomes irreversibly dependent upon progesterone signalling. In pregnancy, persistently elevated progesterone levels ensure survival and integrity of the decidua during the process of trophoblast invasion and placenta formation. In the absence of pregnancy, falling levels of progesterone trigger a cascade of events that results in proteolytic breakdown of the superficial endometrium, focal bleeding and cell death (Finn 1998, Critchley et al. 2001). In this review, we summarise the molecular cues that underpin the decidual process and explore the role of three functionally related transcription factors, p53, FOXO1 and PLZF, in life and death decisions of human endometrial stromal cells.
|
Decidualisation of the endometrial stroma |
|---|
|
TopAbstractIntroductionDecidualisation of the...Transcription factors in...Progesterone - tipping the...PerspectiveReferences |
|---|
Decidualisation is first apparent in the stromal cells surrounding the terminal spiral arteries of the superficial endometrial layer around day 23 of a 28-day cycle. It heralds the end of the limited period of endometrial receptivity (the ‘implantation window’) during which embryo attachment can take place. The elongated spindle-like stromal cells transform into cobblestone-like enlarged decidual cells with multiple club-shaped projections arising from their cell surface (Wynn 1974). In pregnancy, the endometrium is under the continued support of steroid hormones as well as blastocyst-derived signals such as human chorionic gonadotrophin (hCG). This provides the hormonal milieu for full decidualisation of the entire endometrium. The decidua forms a dense cellular matrix that allows coordinated trophoblast invasion while simultaneously protecting the conceptus from maternal and environmental insults (Kliman 2000, Red-Horse et al. 2004).
The distinct morphological appearance of decidualising stromal cells is underpinned by profound biochemical changes. Microarray studies have demonstrated that decidualisation involves sequential reprogramming of functionally related families of genes involved in extracellular matrix organisation, cell adhesion, cytoskeletal organisation, signal transduction, metabolism, differentiation and apoptosis (Giudice 2004). Consequently, upon biochemical reprogramming, the ESCs acquire many new functions that critically govern successful trophoblast invasion and placenta formation. For instance, differentiating ESCs secrete a variety of factors, such as macrophage inflammatory protein-1ß, interleukin (IL)-11, IL-15 and prolactin (PRL), which provide the chemotactic, proliferative and differentiating signals for specialised immune cells (Dimitriadis et al. 2005). Most abundant are uNK cells, which constitute 50–90% of the resident lymphocytes in early gestation. These innate immune cells are a rich source of cytokines and angiogenic growth factors. They are not only involved in conferring immunotolerance towards paternal antigens expressed on the invading trophoblast but also play a role in the remodelling of the spiral arteries prior to endovascular trophoblast invasion (Dosiou & Giudice 2005, Leonard et al. 2006). The decidua also expresses factors that are implicated in the suppression of T cell-dependent immune responses to fetal alloantigens such as the tryptophan-catabolising enzyme indoleamine 2,3-dioxygenase (IDO), tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL) (Popovici et al. 2000, Kayisli et al. 2003, Kudo et al. 2004). Remodelling of the extracellular matrix, characterised by the production of laminin, type IV collagen, fibronectin, and heparan sulphate proteoglycan, and secretion of growth factors and binding proteins such as insulin-like growth factor binding protein-1 (IGFBP-1) critically regulate coordinated trophoblast invasion and differentiation (Fazleabas et al. 2004, Kayisli et al. 2005). Implantation and formation of the placenta are inflammatory processes, and differentiating ESCs express enzymes such as mitochondrial manganese superoxide dismutase (MnSOD) that are involved in oxidative stress defences (Sugino et al. 1996). Furthermore, decidualising stromal cells surrounding the spiral arteries highly express tissue factor (TF, the initiator of the extrinsic coagulation pathway) and plasminogen activator inhibitor-1 (PAI-1, a fibrinolysis inhibitor), emphasising their primary role in maintaining vascular stability prior to menstruation and during endovascular trophoblast invasion (Schatz et al. 2003).
In the absence of pregnancy, falling sex hormone levels induce a switch in the secretory repertoire of differentiated ESCs that triggers a sequence of events leading to menstrual shedding of the superficial endometrial layer. Perhaps the first histological sign of impending endometrial breakdown is uNK cell apoptosis. As uNK cells do not express progesterone receptors (PR), cell death is likely a consequence of paracrine signals derived from PR-positive stromal cells (King 2000). Upon progesterone withdrawal, differentiated stromal cells also produce the chemokines and inflammatory mediators that trigger local infiltration of the endometrium by macrophages and other inflammatory cells. Approximately two days before the onset of menstruation, endometrial epithelial cells show a high degree of apoptosis, a low proliferative index and loss of PR expression. In contrast, stromal cell apoptosis is a later event, which is less pronounced and coincides with increased proliferation rate, persistent PR expression and decreased levels of the anti-apoptotic Bcl-2 protein. These characteristics indicate a high cell turnover in the stromal compartment during menstruation in preparation for the subsequent tissue regeneration (Dahmoun et al. 1999). Conceivably, even limited apoptosis of decidualised cells surrounding the terminal spiral arteries may trigger focal interstitial haemorrhage. Ultimately, the shedding of endometrial tissue requires local and controlled degradation of the extracellular matrix, which in turn is dependent upon the balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). MMPs form a large family of zinc-dependent enzymes with considerable structural homology but distinct substrate specificities (Dong et al. 2002). Although all cellular components in the superficial endometrial layer take part in the premenstrual expression and activation of MMPs, the differentiated stromal cells are thought to be the major source of MMP expression (E Marbaix and P Henriet, personal communication).
Hormonal signals for decidualisation
Decidualisation is beautifully reciprocated in cultured ESCs upon addition of the appropriate hormonal stimuli. Many protocols for in vitro decidualisation have been developed over the last 25 years. Three major points can be deduced from these studies. First, treatment with progesterone for eight or more days, alone or in combination with oestradiol, can induce expression of decidual markers such as PRL or IGFBP-1 in primary cultures, albeit at modest levels. Second, ligands that trigger a persistent increase in intracellular cyclic AMP (cAMP) levels much more rapidly induce expression of decidual marker genes, although the levels are not maintained in long-term cultures. Finally, full decidualisation and sustained expression of the differentiated phenotype requires both elevated cAMP levels and progesterone (Gellersen & Brosens 2003). These culture conditions reflect the in vivo situation. The endometrial stroma in the secretory phase of the cycle is not only exposed to progesterone but also to a number of factors which bind to G-protein coupled receptors (GPCRs) present in stromal cells, resulting in activation of adenylate cyclase, formation of the second messenger cAMP and activation of protein kinase A (PKA). Such ligands include prostaglandin E2, corticotrophin releasing hormone, relaxin and perhaps the circulating pituitary gonadotrophins (Gellersen & Brosens 2003). In pregnancy, trophoblast-derived hCG may further act on gonadotrophin receptors expressed on differentiating endometrial cells. While cAMP can also act in a PKA-independent fashion by binding to the Rap guanine exchange factors Epac (exchange protein activated by cAMP) 1 and 2 (de Rooij et al. 1998, Kawasaki et al. 1998), this pathway does not appear to play a significant role in cAMP-induced decidualisation (Gellersen & Brosens 2003).
In recent years, the regulation of major decidual marker genes, such as PRL, IGFBP-1, and TF, has been widely used as a paradigm for the dissection of the cross-talk between cAMP and progesterone signalling in ESCs. Progesterone actions are mediated by binding and activation of PR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors. Notably, none of the major decidual genes appears to be under direct transcriptional control of activated PR, in keeping with the inability of progesterone to induce ESC differentiation in short-term cultures. This may be attributable to the relative level of expression of two PR isoforms, PR-A and PR-B, which arise from differential promoter usage in a single gene. PR-A lacks the 164 N-terminal amino acids of PR-B, is transcriptionally less active and can transrepress PR-B on palindromic progesterone-responsive elements (Li & O’Malley 2003). It is however the dominant isoform in human decidualising ESC in vivo and in vitro, and in mice, selective deletion of PR-A leads to a defective decidual response to the implanting blastocyst (Brosens et al. 1999, Mote et al. 1999, Mulac-Jericevic & Conneely 2004). In human ESC, emerging evidence suggests a major role for the activated PR, specifically the PR-A isoform, as a scaffold for the recruitment of transcription factors activated, directly or indirectly, in response to cAMP signalling (Gellersen & Brosens 2003). Direct physical interaction has indeed been demonstrated between PR and signal transducer and activator of transcription 5 (STAT5), CCAAT enhancer-binding protein ß (C/EBPß), or forkhead box O (FOXO1) (Owen et al. 1998, Richer et al. 1998, Christian et al. 2002a, Kim et al. 2005). By hijacking these transcription factors, the activated PR acquires control of the diverse gene families involved in decidualisation. More recently, it has become apparent that the cAMP and progesterone signalling pathways also differentially control the expression and activity of a limited number of transcription factors involved in cell fate decisions.
|
Transcription factors in endometrial stroma with implications in cell fate decisions |
|---|
|
TopAbstractIntroductionDecidualisation of the...Transcription factors in...Progesterone - tipping the...PerspectiveReferences |
|---|
Structure and function of PLZF
The promyelocytic leukaemia zinc finger protein (PLFZ) was first identified in acute promyelocytic leukaemia where a reciprocal chromosomal translocation results in expression of fusion proteins between PLZF and retinoic acid receptor 
. The wild-type PLZF belongs to the large family of POZ domain and Krüppel zinc finger (POK) proteins that contain a conserved N-terminal BTB/POZ (bric-a-brac/tramtrack/broad complex, poxvirus and zinc finger) repressor domain and a C-terminal DNA-binding region composed of zinc fingers of the Krüppel type. PLZF has a second repressor domain that interacts with the Eight-Twenty One (ETO) protein. Both PLZF and ETO recruit proteins such as SMRT (silencing mediator for retinoid and thyroid-hormone receptors), N-CoR (nuclear receptor co-repressor), Sin3 and HDACI (histone deacetylase I) to form a multiprotein transrepressor complex (Melnick et al. 2000, Costoya & Pandolfi 2001). In development, PLZF is crucial for limb and axial skeletal patterning, forebrain organisation and hindbrain segmentation (Avantaggiato et al. 1995, Cook et al. 1995, Barna et al. 2000). With regard to reproductive functions, gene deletion studies in mice revealed an essential role for this factor in maintaining spermatogonial stem cells in adults. In addition, PLZF was identified as an androgen-responsive gene in the prostate (Buaas et al. 2004, Costoya et al. 2004, Jiang & Wang 2004). PLZF can confer resistance to apoptosis, partly by transcriptional inhibition of the gene encoding the pro-apoptotic BID protein, a member of the Bcl-2 family (Parrado et al. 2004). Further, PLZF exerts an anti-proliferative effect through suppression of cyclin A transcription (Yeyati et al. 1999).
PLZF in the endometrial stroma
We identified PLZF as an early progesterone-inducible product in cultured human ESCs. Within 2 h of progesterone treatment, PLZF mRNA levels are massively up-regulated while treatment with a cAMP analogue has no effect on its expression. In vivo, PLZF accumulates in the nuclei of stromal cells in the mid-late secretory endometrium (Fahnenstich et al. 2003). Studies in human fibrosarcoma cells indicated that the antiproliferative action of PLZF is reversed by HB–EGF-C, the C-terminal soluble fragment that results from proteolytic cleavage of the membrane-anchored precursor proHB–EGF (heparin-binding epidermal growth factor-like growth factor). HB–EGF-C translocates to the nucleus, interacts with PLZF and triggers its nuclear export, thus reversing cell cycle inhibition (Nanba et al. 2003). In human ESCs, HB–EGF expression is induced by cAMP, enhances the expression of decidual marker proteins, and confers resistance to apoptosis induced by pro-inflammatory cytokines (Chobotova et al. 2005). While the N-terminal cleavage product of proHB–EGF, the mature HB–EGF, is a growth-promoting ligand of the EGF receptor, the role of the by-product HB–EGF-C in ESCs has not been assessed. It is nevertheless tempting to speculate that an altered balance between progesterone-induced antiproliferative and antiapoptotic PLZF and cAMP-induced HB–EGF-C participates in endometrial stromal cell fate decision towards the end of the menstrual cycle.
p53 – a cAMP-inducible proapoptotic, antiproliferative protein with functions beyond tumour suppression
Structure, regulation and tumour suppressor function of p53
Structurally, p53 is a transcription factor with an N-terminal transactivation domain, a core DNA-binding region and a C-terminal tetramerisation domain. Among the target genes activated by p53 are those encoding the pro-apoptotic Bax, NOXA and PUMA members of the Bcl-2 family, the cell cycle inhibitor p21WAF1, growth arrest and DNA damage-inducible gene 45 (GADD45), and mouse double minute-2 (Mdm2) (Levine 1997). Induction of Mdm2 establishes an important negative feedback loop as it binds to p53 at its N-terminus, functions as an E3-ubiquitin ligase, and targets p53 for proteasomal degradation. Transcription-ally inactive p53 mutants, which are found in approximately 50% of all human tumours, fail to induce Mdm2 and consequently p53 accumulates in tumour cells (Lane & Hall 1997, Vogelstein et al. 2000). This phenomenon led originally to the misconception that p53 is an oncogene. A further player in the p53/Mdm2 regulatory loop is the ARF protein (p14ARF in human, p19ARF in the mouse), the product of an alternative transcript from the CDKN2A tumour suppressor locus. It binds to Mdm2, inhibits its activity, and thus allows p53 to escape from Mdm2-mediated degradation (Stott et al. 1998, Oren et al. 2002). Significantly, the CDKN2A locus is frequently deleted or silenced in different tumours (Sharpless & Chin 2003).
While the TP53 gene is constitutively transcribed, the level of p53 protein is kept extremely low under physiological conditions through rapid proteasomal degradation of newly synthesised protein. Only in response to genotoxic insults, such as exposure to UV light, irradiation, oncogene activation, hypoxia or chemotherapeutic agents, p53 is stabilised, accumulates rapidly, and becomes transcriptionally active. It then functions, relating to its role as a tumour suppressor, to induce cell cycle arrest or apoptotic cell death. In addition to cell cycle arrest in G1, p53 can also arrest cells in G2 and inhibit entry into mitosis. This occurs partly through induction of three p53 target genes (GADD45, 14–3–3 and p21WAF1) that simultaneously inhibit transcription of the Cdc2 cyclin-dependent kinase (Taylor & Stark 2001). Cell cycle arrest may be permanent or transient, allowing repair of damaged DNA before resumption of replication. Apoptosis will irreversibly remove damaged cells from the organism. Both mechanisms serve to prevent the emergence of cell populations harbouring oncogenic mutations (Ryan et al. 2001).
Subcellular localisation, activity and stability of p53 are interdependent and subject to complex regulation by posttranslational modifications including phosphorylation, acetylation and sumoylation (Ryan et al. 2001). In addition to direct transcriptional activation of target genes, p53 exerts many of its functions through protein/protein interactions. In fact, gene expression profiling has revealed that many responsive genes are actually repressed by p53 through both direct and indirect mechanisms (Mirza et al. 2003, Kho et al. 2004).
p53 in the endometrial stroma
In the course of cAMP-induced decidualisation, high levels of nuclear p53 protein accumulate in cultured ESC, and intense nuclear p53 immunoreactivity is observed in endometrial stromal cells during the secretory phase of the cycle (Pohnke et al. 2004). There are several interesting aspects to p53 expression in human endometrial stroma. First, the kinetics of its induction in response to cAMP signalling are not typical of a stress response. Expression of p53 is a delayed response, requiring between 2 to 4 days of cAMP stimulation, and coincides with the appearance of morphological and biochemical signs of decidualisation. Secondly, the accumulation of p53 protein is not due to enhanced transcription of the TP53 gene but a consequence of protein stabilisation. Finally, progesterone does not induce or enhance p53 expression or alter its DNA-binding activity (Pohnke et al. 2004).
What function might p53 serve in the decidualising endometrium? It is unlikely that p53 induces extensive apoptosis in differentiating cells. While cAMP signalling modestly increases the apoptotic fraction in culture, this only affects approximately 12–15% of cells, whereas p53 accumulation occurs in virtually all cells (J J Brosens & E W-E Lam, unpublished observations). Instead, there appears to be a close link between p53 levels and the differentiation status of ESCs. For instance, withdrawal of the differentiation stimulus from decidualised cells results in reversal of the differentiated to the undifferentiated proliferative phenotype along with disappearance of p53 protein levels. It is possible that increased p53 levels in decidualised stromal cells during the secretory phase of the cycle constitute a pool of transcriptionally inert proteins that are activated upon withdrawal of survival signals prior to menstruation. In a non-activated state, p53 could still exert repressor function by protein/protein interactions. We observed direct physical association and transrepression between p53 and the leucine zipper transcription factor C/EBP ß which is an important mediator of the cAMP signal in decidualising ESC (Christian et al. 2002a,b, Schneider-Merck et al. 2006). Transcriptionally activated p53 in turn might be involved in regulation of MMP expression. A perfect p53 binding site has been identified in the MMP-2 promoter, contiguous with binding motifs for activating protein-2 (AP2) and YB-1. Interaction between these transcription factors yields ternary complexes that lead to synergistic activation of MMP-2 transcription (Bian & Sun 1997, Mertens et al. 2002). It is thus conceivable that p53 in decidualised ESC participates in MMP-2 expression, a prerequisite for endometrial breakdown and subsequent tissue regeneration. Importantly, MMP-2 expression is up-regulated in decidualised ESC upon progesterone withdrawal (Irwin et al. 1996), indicating the release from a suppressive mechanism.
Accumulation of wild-type p53 in the absence of stress is an unusual phenomenon in most cells but not in female reproductive tissues. In the ovary, p53 appears to act as a proapoptotic mediator involved in maintaining tissue homeostasis during the cyclical process of follicle selection (Makrigiannakis et al. 2000). A different role is suggested for p53 in normal mammary tissue. In the quiescent mammary gland, p53 localises to the cytoplasm of the ductal epithelium and appears refractory to activation in response to ionising radiation. However, upon 6 h of treatment with hCG, p53 is recruited to the nucleus and can be functionally activated by irradiation to induce target gene transcription (Kupperwasser et al. 2000). In the rat, elevated oestrogen and progesterone levels during pregnancy also induce sustained nuclear accumulation of p53 capable of responding to carcinogenic challenges. This ability of nuclear p53 to survey and maintain genome integrity in breast tissue is thought to account for the protective effect of pregnancy against the incidence of breast cancer. In the murine mammary epithelium, high nuclear levels of p53 are maintained throughout pregnancy, weaning and involution (Sivaraman et al. 2001). The elevated p53 levels may partly be attributable to a progesterone-dependent increase in the levels of tumour suppressor p19ARF during pregnancy, lactation and involution. The role of p19ARF could be to sustain a normal proliferation rate of the mammary epithelium in pregnancy while inducing apoptosis in a p53-dependent fashion upon weaning and involution (Yi et al. 2004). The decidua also expands phenomenally during pregnancy to accommodate the growing fetus. Conceivably, decidual p53 may therefore also serve as a ‘guardian of the genome’ during gestation. Importantly, both activated and non-activated p53 can serve complementary roles in the maintenance of genome integrity (Albrechtsen et al. 1999).
FOXO1 – a cAMP-inducible, progesterone-regulated switch at the crossroads of apoptosis and survival
Structure and function of FOXO1
The FOXO (forkhead box O) proteins constitute a subclass of the winged helix of Forkhead box (FOX) class of transcription factors which are helix-turn-helix DNA-binding proteins with a butterfly-like appearance. FOXO transcription factors are critical mediators in cell fate decisions in response to growth factor, hormonal and environmental cues (Accili & Arden 2004). Although structurally unrelated, they share striking functional homologies with p53. Both are involved in the control of cell cycle arrest and the induction of apoptosis. This is, at least in part, attributable to the fact that they share common target genes such as GADD45, p21WAF1 and FasL (You & Mak 2005).
The transcriptional activity of FOXO proteins is critically regulated by their subcellular localisation. Growth factor signalling through the phosphatidylinositol 3-kinase (PI3K) pathway leads to phosphorylation of the serine/threonine kinase Akt (also termed protein kinase B) that in turn phosphorylates downstream target proteins, including the FOXO transcription factors. Akt-dependent phosphorylation of nuclear FOXO generates binding sites for the 14–3–3 chaperone protein which releases FOXO factors from their target DNA and causes translocation to the cytoplasm. Growth factor-dependent nuclear exclusion and inactivation of FOXO thus leads to reduced expression of proapoptotic and antiproliferative target genes and promotes cell survival (Brunet et al. 1999, Burgering & Kops 2002).
FOXO1 in the endometrial stroma
Of the three human FOXO proteins (FOXO1, FOXO3a, and FOXO4), FOXO1 is markedly induced upon decidualisation both in vivo and in vitro, and is involved in regulating the expression of decidual marker genes, such as PRL and IGFBP-1. The promoters of both genes are activated by multimeric transcription factor complexes containing FOXO1 which assemble in response to an interplay of cAMP- and progesterone-dependent signals (Christian et al. 2002b, Gellersen & Brosens 2003, Kim et al. 2003, 2005). Furthermore, the expression and activity of FOXO1 itself is subject to intricate control mechanisms involving both the PKA pathway and the ligand-activated nuclear PR. Within three days of cAMP treatment, cultured ESC up-regulate FOXO1 mRNA and protein, and this response is markedly enhanced by progestin although treatment with progestin alone does not induce FOXO1 expression (Labied et al. 2006). A known FOXO target gene is BIM (BCL2 L11) which encodes the proapoptotic Bcl-2 homology 3 domain-only protein Bim (Dijkers et al. 2000, Sunters et al. 2003). Bim expression increases in the endometrium prior to menstruation and in culture upon activation of the cAMP pathway in a FOXO1-dependent manner. However, despite the fact that FOXO1 levels are even higher in cells treated with a combination of cAMP and progestin, Bim expression is inhibited under these conditions (Labied et al. 2006). The solution to this paradox lies in the fact that cAMP causes nuclear accumulation of FOXO1 while added progestin induces nuclear exit and thus inactivation of a large fraction of the total FOXO1 protein pool. Withdrawal of progestin in turn results in rapid nuclear re-accumulation of FOXO1, increased expression of Bim and increased cell death (Labied et al. 2006). Another FOXO target gene, Fas ligand (FASLG), has also been implicated in regulating ESC apoptosis (Chatzaki et al. 2001, Kayisli et al. 2003) and is likely subject to similar regulatory mechanisms as described for BIM.
These findings suggest a critical role for FOXO1 in mediating the proapoptotic pathway initiated by progesterone withdrawal at the end of the menstrual cycle (Fig.1
). This is underpinned by the observation that silencing of FOXO1 expression in differentiating ESC completely abrogates apoptosis induced by progestin withdrawal, suggesting that progesterone serves as a survival factor in decidualised ESCs through partial cytoplasmic retention and inactivation of FOXO1 (Labied et al. 2006). Interestingly, hormone-dependent nuclear exclusion of FOXO1 has also emerged as a survival mechanism in ovarian granulosa cells. Here, follicle stimulating hormone (FSH) provides the survival signal to prevent atresia in the antral follicles by promoting phosphorylation, cytoplasmic translocation and inactivation of FOXO1 in a PI3K-dependent fashion (Cunningham et al. 2003).
|
|
Progesterone – tipping the balance |
|---|
|
TopAbstractIntroductionDecidualisation of the...Transcription factors in...Progesterone - tipping the...PerspectiveReferences |
|---|
. In the luteal phase of the menstrual cycle, p53 and FOXO1 have accumulated under the influence of the activated PKA pathway, but progesterone-signalling has led to inactivation of a large portion of FOXO1 while PLZF expression has been upregulated. Under these conditions, the small active pool of FOXO1 preferentially induces differentiation-specific decidual genes, and the pro-survival function of PLZF outweighs the proapoptotic potential of p53. Upon progesterone withdrawal, however, PLZF expression is no longer supported, while FOXO1 is rapidly and massively re-activated from the cytoplasmic standby pool and cooperates with p53 in the initiation of apoptosis.
|
|
Perspective |
|---|
|
TopAbstractIntroductionDecidualisation of the...Transcription factors in...Progesterone - tipping the...PerspectiveReferences |
|---|
|
Acknowledgements |
|---|
|
References |
|---|
|
TopAbstractIntroductionDecidualisation of the...Transcription factors in...Progesterone - tipping the...PerspectiveReferences |
|---|
Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmuller L & Deppert W 1999 Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 18 7706–7717.[CrossRef][Web of Science][Medline]
Avantaggiato V, Pandoli PP, Ruthardt M, Hawe N, Acampora D, Pelicci PG & Simeone A 1995 Developmental analysis of murine promyelocytic leukemia zinc finger (PLZF) gene expression: Implications for the neuromeric model of the forebrain organization. Journal of Neuroscience 15 4927–4942.[Abstract]
Barna M, Hawe N, Niswander L & Pandolfi PP 2000 Plzf regulates limb and axial skeletal patterning. Nature Genetics 25 166–172.[CrossRef][Web of Science][Medline]
Bian J & Sun Y 1997 Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Molecular and Cellular Biology 17 6330–6338.
Brosens JJ, Hayashi N & White JO 1999 Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells. Endocrinology 140 4809–4820.
Brosens JJ, Pijnenborg R & Brosens IA 2002 The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. American Journal of Obstetrics and Gynecology 187 1416–1423.[CrossRef][Web of Science][Medline]
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J & Greenberg ME 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 857–868.[CrossRef][Web of Science][Medline]
Buaas FW, Kirsh AL, Sharma M, McLean DJ, Morris HL, Griswold MD, de Rooij DG & Braun RE 2004 Plzf is required in adult male germ cells for stem cell self-renewal. Nature Genetics 36 647–652.[CrossRef][Web of Science][Medline]
Burgering BM & Kops GJ 2002 Cell cycle and death control: long live Forkheads. Trends in Biochemical Sciences 27 352–360.[CrossRef][Web of Science][Medline]
Chatzaki E, Makrigiannakis A, Margioris AN, Kouimtzoglou E & Gravanis A 2001 The Fas/FasL apoptotic pathway is involved in 
-opioid-induced apoptosis of human endometrial stromal cells. Molecular Human Reproduction 7 867–874.
Chobotova K, Karpovich N, Carver J, Manek S, Gullick WJ, Barlow DH & Mardon HJ 2005 Heparin-binding epidermal growth factor and its receptors mediate decidualization and potentiate survival of human endometrial stromal cells. Journal of Clinical Endocrinology and Metabolism 90 913–919.
Christian M, Pohnke Y, Kempf R, Gellersen B & Brosens JJ 2002a Functional association of PR and CCAAT/enhancer-binding protein ß isoforms: Promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells. Molecular Endocrinology 16 141–154.
Christian M, Zhang X, Schneider-Merck T, Unterman TG, Gellersen B, White JO & Brosens JJ 2002b Cyclic AMP-induced forkhead transcription factor, FKHR, cooperates with CCAAT/enhancer-binding protein ß in differentiating human endometrial stromal cells. Journal of Biological Chemistry 277 20825–20832.
Cook M, Gould A, Brand N, Davies J, Strutt P, Shaknovich R, Licht J, Waxman S, Chen Z, Gluecksohn-Waelsch S et al. 1995 Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain. PNAS 92 2249–2253.
Costoya JA & Pandolfi PP 2001 The role of promyelocytic leukemia zinc finger and promyelocytic leukemia in leukemogenesis and development. Current Opinion in Hematology 8 212–217.[CrossRef][Web of Science][Medline]
Costoya JA, Hobbs RN, Barna M, Cattoretti G, Manova K, Sukhwani M, Orwig KE, Wolgemuth DJ & Pandolfi PP 2004 Essential role of Plzf in maintenance of spermatogonial stem cells. Nature Genetics 36 551–553.[CrossRef][Web of Science][Medline]
Critchley HO, Kelly RW, Brenner RM & Baird DT 2001 The endocrinology of menstruation–a role for the immune system. Clinical Endocrinology 55 701–710.[CrossRef][Medline]
Cunningham MA, Zhu Q, Unterman TG & Hammond JM 2003 Follicle-stimulating hormone promotes nuclear exclusion of the forkhead transcription factor FoxO1a via phosphatidylinositol 3-kinase in procine granulosa cells. Endocrinology 144 5585–5594.
Dahmoun M, Boman K, Cajander S, Westin P & Backstrom T 1999 Apoptosis, proliferation, and sex hormone receptors in superficial parts of human endometrium at the end of the secretory phase. Journal of Clinical Endocrinology and Metabolism 84 1737–1743.
de Rooij J, Zwartkruis FJT, Verheijen MHG, Cool RH, Nijman SMB, Wittinghofer A & Bos JL 1998 Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396 474–477.[CrossRef][Medline]
Dey SK, Lim H, Das SK, Reese J, Paria BC, Daikoku T & Wang H 2004 Molecular cues to implantation. Endocrine Reviews 25 341–373.
Dijkers PF, Medema RH, Lammers JW, Koenderman L & Coffer PJ 2000 Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Current Biology 10 1201–1204.[CrossRef][Web of Science][Medline]
Dimitriadis E, White CA, Jones RL & Salamonsen LA 2005 Cytokines, chemokines and growth factors in endometrium related to implantation. Human Reproduction Update 11 613–630.
Dmowski WP, Ding J, Shen J, Rana N, Fernandez BB & Braun DP 2001 Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. Human Reproduction 16 1802–1808.
Dong JC, Dong H, Campana A & Bischof P 2002 Matrix metalloproteinases and their specific tissue inhibitors in menstruation. Reproduction 123 621–631.[Abstract]
Dosiou C & Giudice LC 2005 Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. Endocrine Reviews 26 44–62.
Fahnenstich J, Nandy A, Milde-Langosch K, Schneider-Merck T, Walther N & Gellersen B 2003 Promyelocytic leukemica zinc finger protein (PLZF) is a glucocorticoid- and progesterone-regulated transcription factor in human endometrial stromal cells and myometrial smooth muscle cells. Molecular Human Reproduction 9 611–623.
Fazleabas AT, Kim JJ & Strakova Z 2004 Implantation: embryonic signals and the modulation of the uterine environment – a review. Placenta 25 (Supplement 1) S26–S31.[CrossRef][Web of Science][Medline]
Finn CA 1987 Why do women and some other primates menstruate? Perspectives in Biology and Medicine 30 566–574.[Web of Science][Medline]
Finn CA 1998 Menstruation: a nonadaptive consequence of uterine evolution. The Quarterly Review of Biology 73 163–173.[CrossRef][Medline]
Gebel HM, Braun DP, Tambur A, Frame D, Rana N & Dmowski WP 1998 Spontaneous apoptosis of endometrial tissue is impaired in women with endometriosis. Fertility and Sterility 69 1042–1047.[CrossRef][Web of Science][Medline]
Gellersen B & Brosens JJ 2003 Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair. Journal of Endocrinology 178 357–372.[Abstract]
Giudice LC 2004 Microarray expression profiling reveals candidate genes for human uterine receptivity. American Journal of Pharmacogenomics 4 299–312.[CrossRef][Medline]
Gylfason JT, Dang D, Petursdottir V, Benediktsdottir KR, Geirsson RT, Poindexter A, Mitchell-Leef D, Buster JE, Carson SA, Simpson JL et al. 2005 Quantitative DNA perturbations of p53 in endometriosis: analysis of American and Icelandic cases. Fertility and Sterility 84 1388–1394.[CrossRef][Web of Science][Medline]
Irwin JC, Kirk D, Gwatkin RBL, Navre M, Cannon P & Giudice LC 1996 Human endometrial matrix metalloproteinase-2, a putative menstrual proteinase: Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle. Journal of Clinical Investigation 97 438–447.[Web of Science][Medline]
Jiang F & Wang Z 2004 Identification and characterization of PLZF as a prostatic androgen-responsive gene. Prostate 59 426–435.[CrossRef][Web of Science][Medline]
Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE & Graybiel AM 1998 A family of cAMP-binding proteins that directly activate Rap1. Science 282 2275–2279.
Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R & Arici A 2003 Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. Journal of Immunology 171 2305–2313.
Kayisli UA, Korgun ET, Akkoyunlu G, Arici A & Demir R 2005 Expression of integrin 5 and integrin ß4 and their extracellular ligands fibronectin and laminin in human decidua during early pregnancy and its sex steroid-mediated regulation. Acta Histochemica 107 173–185.[CrossRef][Web of Science][Medline]
Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET & Yu Q 2004 p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. Journal of Biological Chemistry 279 21183–21192.
Kim JJ, Buzzio OL, Li S & Lu Z 2005 Role of FOXO1A in the regulation of insulin-like growth factor-binding protein-1 in human endometrial cells: interaction with progesterone receptor. Biology of Reproduction 73 833–839.
Kim JJ, Taylor HS, Akbas GE, Foucher I, Trembleau A, Jaffe RC, Fazleabas AT & Unterman TG 2003 Regulation of insulin-like growth factor binding protein-1 promoter activity by FKHR and HOXA10 in primate endometrial cells. Biology of Reproduction 68 24–30.
King A 2000 Uterine leukocytes and decidualization. Human Reproduction Update 6 28–36.
Kliman HJ 2000 Uteroplacental blood flow. The story of decidualization, menstruation, and trophoblast invasion. American Journal of Pathology 157 1759–1768.
Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M et al. 1997 PTEN1 is frequently mutated in primary endometrial carcinomas. Nature Genetics 17 143–144.[CrossRef][Web of Science][Medline]
Kudo Y, Hara T, Katsuki T, Toyofuku A, Katsura Y, Takikawa O, Fujii T & Ohama K 2004 Mechanisms regulating the expression of indoleamine 2,3-dioxygenase during decidualization of human endometrium. Human Reproduction 19 1222–1230.
Kupperwasser C, Pinkas J, Hurlbut GD, Naber SP & Jerry DJ 2000 Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Research 60 2732–2729.
Labied S, Kajihara T, Madureira PA, Fusi L, Jones MC, Higham JM, Varshochi R, Francis JM, Zoumpoulidou G, Essafi A et al. 2006 Progestins regulate the expression and activity of the Forkhead transcription factor FOXO1 in differentiating human endometrium. Molecular Endocrinology 20 35–44.
Lane DP & Hall PA 1997 MDM2 – arbiter of p53' s destruction. Trends in Biochemical Sciences 22 372–374.[CrossRef][Web of Science][Medline]
Leonard S, Murrant C, Tayade C, van den Heuvel M, Watering R & Croy BA 2006 Mechanisms regulating immune cell contributions to spiral artery modification – Facts and hypotheses – A review. Placenta 27 40–46.[CrossRef]
Levine AJ 1997 p53, the cellular gatekeeper for growth and division. Cell 88 323–331.[CrossRef][Web of Science][Medline]
Li X & O’Malley BW 2003 Unfolding the action of progesterone receptor. Journal of Biological Chemistry 278 39261–39264.
Makrigiannakis A, Amin K, Coukos G, Tilly JL & Coutifaris C 2000 Regulated expression and potential roles of p53 and Wilms’ tumor suppressor gene (WT1) during follicular development in the human ovary. Journal of Clinical Endocrinology and Metabolism 85 449–459.
Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ, Lutterbach B, Hiebert SW & Licht JD 2000 The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Molecular and Cellular Biology 20 2075–2086.
Mertens PR, Steinmann K, Alfonso-Jaume MA, En-Nia A, Sun Y & Lovett DH 2002 Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. Journal of Biological Chemistry 277 24875–24882.
Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F, Ding W, Hutchins B, Hockenberry T, Kirschmeier P et al. 2003 Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22 3645–3654.[CrossRef][Web of Science][Medline]
Mote PA, Balleine RL, McGowan EM & Clarke CL 1999 Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 84 2963–2971.
Mulac-Jericevic B & Conneely OM 2004 Reproductive tissue selective actions of progesterone receptors. Reproduction 128 139–146.
Nanba D, Mammoto A, Hashimoto K & Higashiyama S 2003 Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. Journal of Cell Biology 163 489–502.
Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Martinez Leal JF, Maya R, Moas M, Seger R, Taya Y et al. 2002 Regulation of p53. Intricate loops and delicate balances. Annals of the New York Academy of Sciences 973 374–383.[Web of Science][Medline]
Owen GI, Richer JK, Tung L, Takimoto G & Horwitz KB 1998 Progesterone regulates transcription of the p21WAF1 cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. Journal of Biological Chemistry 273 10696–10701.
Parrado A, Robledo M, Moya-Quiles MR, Marín LA, Chomienne C, Padua RA & Álvarez-López MR 2004 The promyelocytic leukemia zinc finger protein down-regulates apoptosis and expression of the proapoptotic BID protein in lymphocytes. PNAS 101 1898–1903.
Pohnke Y, Schneider-Merck T, Fahnenstich J, Kempf R, Christian M, Milde-Langosch K, Brosens JJ & Gellersen B 2004 Wild-type p53 protein is up-regulated upon cyclic AMP-induced differentiation of human endometrial stromal cells. Journal of Clinical Endocrinology and Metabolism 89 5233–5244.
Popovici RN, Kao L-C & Giudice LC 2000 Discovery of new inducible genes in in vitro decidualized human endometrial stromal cells using microarray technology. Endocrinology 141 3510–3513.
Red-Horse K, Zhou Y, Genbacev O, Prakobphol A, Foulk R, McMaster M & Fisher SJ 2004 Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. Journal of Clinical Investigation 114 744–754.[CrossRef][Web of Science][Medline]
Richer JK, Lange CA, Manning NG, Owen G, Powell R & Horwitz KB 1998 Convergence of progesterone with growth factor and cytokine signaling in breast cancer – Progesterone receptors regulate signal transducers and activators of transcription expression and activity. Journal of Biological Chemistry 273 31317–31326.
Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC & Berchuck A 1998 PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clinical Cancer Research 4 3005–3010.[Abstract]
Ryan KM, Phillips AC & Vousden KH 2001 Regulation and function of the p53 tumor suppressor protein. Current Opinion in Cell Biology 13 332–337.[CrossRef][Web of Science][Medline]
Sakuragi N, Watari H, Ebina Y, Yamamoto R, Steiner E, Koelbl H, Yano M, Tada M & Moriuchi T 2005 Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. International Journal of Cancer 116 514–519.[Medline]
Schatz F, Krikun G, Caze R, Rahman M & Lockwood CJ 2003 Progestin-regulated expression of tissue factor in decidual cells: implications in endometrial hemostasis, menstruation and angiogenesis. Steroids 68 849–860.[CrossRef][Web of Science][Medline]
Schneider-Merck T, Pohnke Y, Kempf R, Christian M, Brosens JJ & Gellersen B 2006 Physical interaction and mutual transrepression between CCAAT/enhancer-binding protein ß (C/EBPß) and the p53 tumor suppressor. Journal of Biological Chemistry 281 269–278.
Sharpless E & Chin L 2003 The INK4a/ARF locus and melanoma. Oncogene 22 3092–3098.[CrossRef][Web of Science][Medline]
Shazand K, Baban S, Prive C, Malette B, Croteau P, Lagace M, Racine JB & Hugo P 2004 FOXO1 and c-jun transcription factors mRNA are modulated in endometriosis. Molecular Human Reproduction 10 871–877.
Sivaraman L, Conneely OM, Medina D & O’Malley BW 2001 p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. PNAS 98 12379–12384.
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH et al. 1998 The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. The EMBO Journal 17 5001–5014.[CrossRef][Web of Science][Medline]
Sugino N, Shimamura K, Takiguchi S, Tamura H, Ono M, Nakata M, Nakamura Y, Ogino K, Uda T & Kato H 1996 Changes in activity of superoxide dismutase in the human endometrium throughout the menstrual cycle and in early pregnancy. Human Reproduction 11 1073–1078.
Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC & Lam EW 2003 FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. Journal of Biological Chemistry 278 49795–49805.
Taylor WR & Stark GR 2001 Regulation of the G2/M transition by p53. Oncogene 20 1803–1815.[CrossRef][Web of Science][Medline]
Vogelstein B, Lane D & Levine AJ 2000 Surfing the p53 network. Nature 408 307–310.[CrossRef][Medline]
Wynn RM 1974 Ultrastructural development of the human decidua. American Journal of Obstetrics and Gynecology 118 652–670.[Web of Science][Medline]
Yeyati PL, Shaknovich R, Boterashvili S, Li J, Ball HJ, Waxman S, Nason-Burchenal K, Dmitrovsky E, Zelent A & Licht JD 1999 Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 18 925–934.[CrossRef][Web of Science][Medline]
Yi Y, Shepard A, Kittrell F, Mulac-Jericevic B, Medina D & Said TK 2004 p19ARF determines the balance between normal cell proliferation rate and apoptosis during mammary gland development. Molecular Biology of the Cell 15 2302–2311.
You H & Mak TW 2005 Crosstalk between p53 and FOXO transcription factors. Cell Cycle 4 37–38.[Web of Science][Medline]
Received in final form 6 April 2006
Accepted 15 April 2006
Made available online as an Accepted Preprint 18 April 2006
This article has been cited by other articles:
|
|
 |
|
  B. Gellersen, M.S. Fernandes, and J.J. Brosens Non-genomic progesterone actions in female reproduction Hum. Reprod. Update, January 1, 2009; 15(1): 119 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Cloke, K. Huhtinen, L. Fusi, T. Kajihara, M. Yliheikkila, K.-K. Ho, G. Teklenburg, S. Lavery, M. C. Jones, G. Trew, et al. The Androgen and Progesterone Receptors Regulate Distinct Gene Networks and Cellular Functions in Decidualizing Endometrium Endocrinology, September 1, 2008; 149(9): 4462 - 4474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. K. Alam, T. Konno, N. Sahgal, L. Lu, and M. J. Soares Decidual Cells Produce a Heparin-binding Prolactin Family Cytokine with Putative Intrauterine Regulatory Actions J. Biol. Chem., July 4, 2008; 283(27): 18957 - 18968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Lu, J. Hardt, and J.J. Kim Global analysis of genes regulated by HOXA10 in decidualization reveals a role in cell proliferation Mol. Hum. Reprod., June 1, 2008; 14(6): 357 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Minici, F. Tiberi, A. Tropea, M. Orlando, M. F. Gangale, F. Romani, S. Campo, A. Bompiani, A. Lanzone, and R. Apa Endometriosis and human infertility: a new investigation into the role of eutopic endometrium Hum. Reprod., March 1, 2008; 23(3): 530 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Takano, Z. Lu, T. Goto, L. Fusi, J. Higham, J. Francis, A. Withey, J. Hardt, B. Cloke, A. V. Stavropoulou, et al. Transcriptional Cross Talk between the Forkhead Transcription Factor Forkhead Box O1A and the Progesterone Receptor Coordinates Cell Cycle Regulation and Differentiation in Human Endometrial Stromal Cells Mol. Endocrinol., October 1, 2007; 21(10): 2334 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Feroze-Zaidi, L. Fusi, M. Takano, J. Higham, M. S. Salker, T. Goto, S. Edassery, K. Klingel, K. M. Boini, M. Palmada, et al. Role and Regulation of the Serum- and Glucocorticoid-Regulated Kinase 1 in Fertile and Infertile Human Endometrium Endocrinology, October 1, 2007; 148(10): 5020 - 5029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.J. Kim, H.S. Taylor, Z. Lu, O. Ladhani, J.M. Hastings, K.S. Jackson, Y. Wu, S.W. Guo, and A.T. Fazleabas Altered expression of HOXA10 in endometriosis: potential role in decidualization Mol. Hum. Reprod., May 1, 2007; 13(5): 323 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Jackson, A. Brudney, J. M. Hastings, P. A. Mavrogianis, J. J. Kim, and A. T. Fazleabas The Altered Distribution of the Steroid Hormone Receptors and the Chaperone Immunophilin FKBP52 in a Baboon Model of Endometriosis Is Associated With Progesterone Resistance During the Window of Uterine Receptivity Reproductive Sciences, February 1, 2007; 14(2): 137 - 150. [Abstract] [PDF]
|
|
|
|
 |
|
 S. M. K. Alam, T. Konno, G. Dai, L. Lu, D. Wang, J. H. Dunmore, A. R. Godwin, and M. J. Soares A uterine decidual cell cytokine ensures pregnancy-dependent adaptations to a physiological stressor Development, January 15, 2007; 134(2): 407 - 415. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
